Liraglutide (Victoza / Saxenda)
liraglutide injection, once-daily subcutaneous administration
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| T2DM — glycemic control (Victoza) | Adults and pediatric patients ≥10 years | Adjunct to diet/exercise; mono or combination | FDA Approved |
| CV risk reduction in T2DM — reduce MACE in established CVD (Victoza) | Adults with T2DM + established CVD | Adjunct to standard of care | FDA Approved |
| Chronic weight management (Saxenda) | Adults with BMI ≥30 or ≥27 + comorbidity; adolescents ≥12 years with BMI corresponding to ≥30 | Adjunct to reduced-calorie diet and exercise | FDA Approved |
Liraglutide was the first GLP-1 receptor agonist to demonstrate cardiovascular benefit in a dedicated outcomes trial (LEADER), establishing a 13% reduction in major adverse cardiovascular events and a 22% reduction in cardiovascular death in patients with type 2 diabetes and high cardiovascular risk. Victoza is the only GLP-1 RA currently approved for both adults and pediatric patients aged 10 years and older with type 2 diabetes. The same molecule at a higher dose (3.0 mg daily) is marketed as Saxenda for chronic weight management. Liraglutide should not be co-administered with other liraglutide-containing products or other GLP-1 receptor agonists.
Polycystic ovary syndrome (PCOS): Liraglutide at 1.2–1.8 mg daily has been studied as an adjunct to improve metabolic parameters and support weight loss in women with PCOS and obesity. Evidence quality: Low-Moderate (small RCTs; not guideline-recommended as primary therapy).
Dosing
Victoza — Type 2 Diabetes (Adults)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — glycemic control (new start) | 0.6 mg SC daily × 1 week | 1.2 mg daily | 1.8 mg daily | 0.6 mg is GI tolerability dose only — not therapeutic for glucose control Uptitrate to 1.8 mg after ≥1 week on 1.2 mg if additional control needed |
| T2DM — add-on to metformin, SU, TZD, or insulin | 0.6 mg SC daily × 1 week | 1.2–1.8 mg daily | 1.8 mg daily | Consider reducing SU or insulin dose to lower hypoglycemia risk Same titration regardless of background therapy |
| T2DM + established CVD — MACE reduction | 0.6 mg SC daily × 1 week | 1.8 mg daily | 1.8 mg daily | LEADER trial used 1.8 mg (or max tolerated dose); 13% MACE reduction Target 1.8 mg for CV benefit; lower doses not studied for CV outcomes |
Victoza — Pediatric Patients (≥10 Years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — glycemic control (pediatric) | 0.6 mg SC daily × ≥1 week | 0.6–1.8 mg daily | 1.8 mg daily | Escalate in 0.6 mg increments, each ≥1 week apart Higher hypoglycemia risk in pediatrics regardless of concomitant therapy |
Saxenda — Chronic Weight Management
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Weight management (adults: BMI ≥30 or ≥27 + comorbidity) | 0.6 mg SC daily × 1 week | 3.0 mg daily | 3.0 mg daily | 5-week escalation: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg Each step is 1 week; discontinue if <4% weight loss at 16 weeks |
If more than 3 days have elapsed since the last liraglutide dose, reinitiate at 0.6 mg daily and retitrate at clinician discretion. This prevents the GI intolerance that occurs when restarting at a higher dose after a gap. Liraglutide can be injected at any time of day, with or without meals, in the abdomen, thigh, or upper arm. When used with insulin, administer as separate injections (never mix), but they may be injected in the same body region. Rotate injection sites within each region to reduce the risk of cutaneous amyloidosis.
Pharmacology
Mechanism of Action
Liraglutide is an acylated human GLP-1 analog with 97% amino acid sequence homology to endogenous GLP-1(7-37). A single amino acid substitution (arginine for lysine at position 34) and the attachment of a C16 fatty acid (palmitic acid) via a glutamic acid spacer at position 26 enable non-covalent albumin binding, which protects the molecule from DPP-4 degradation and extends the half-life to approximately 13 hours — permitting once-daily dosing. Liraglutide activates the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion via increased intracellular cAMP, while simultaneously suppressing glucagon release from alpha cells. It also delays gastric emptying, promotes central satiety, and reduces caloric intake. These combined effects produce clinically meaningful reductions in blood glucose, body weight, and systolic blood pressure.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | SC bioavailability ~55%; Tmax 8–12 hours post-injection; dose-proportional across 0.6–1.8 mg; AUC from thigh 22% lower than abdomen but considered clinically comparable | Once-daily dosing at any time of day, with or without meals; no clinically meaningful difference between injection sites |
| Distribution | Apparent Vd ~13 L; >98% albumin-bound; at 1.8 mg steady-state mean concentration ~128 ng/mL | Albumin binding is the primary protraction mechanism; binding not affected by renal or hepatic impairment |
| Metabolism | Endogenous proteolytic degradation similar to large proteins; not organ-specific; no single organ is the major route of elimination; no intact liraglutide detected in urine or feces | No CYP450 involvement; negligible metabolic drug interaction potential; no dose adjustment for hepatic or renal impairment |
| Elimination | t½ ~13 hours; clearance ~1.2 L/h; excreted as metabolites via urine (~6%) and feces (~5%); no intact molecule in excreta | Supports once-daily dosing; if >3 days missed, reinitiate at 0.6 mg to avoid GI intolerance |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 18% (1.2 mg); 20% (1.8 mg) | Versus 5% placebo; dose-related; most common during first 2–3 months; typically self-limiting |
| Diarrhea | 10% (1.2 mg); 12% (1.8 mg) | Versus 4% placebo; can contribute to dehydration |
| Headache | 11% (1.2 mg); 10% (1.8 mg) | Versus 7% placebo; usually mild and transient |
| Decreased appetite | 10% (1.2 mg); 9% (1.8 mg) | Versus 1% placebo; pharmacological effect contributing to weight loss |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nasopharyngitis | 9% (1.2 mg); 10% (1.8 mg) | Versus 8% placebo; likely not drug-related |
| Vomiting | 6% (1.2 mg); 9% (1.8 mg) | Versus 2% placebo; primarily during dose escalation |
| Dyspepsia | 4% (1.2 mg); 7% (1.8 mg) | Versus 1% placebo |
| Upper respiratory tract infection | 7% (1.2 mg); 6% (1.8 mg) | Versus 6% placebo; similar to placebo |
| Constipation | 5% (1.2 mg); 5% (1.8 mg) | Versus 1% placebo; related to delayed gastric emptying |
| Back pain | 4% (1.2 mg); 5% (1.8 mg) | Versus 3% placebo |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Acute pancreatitis | 2.7 per 1,000 pt-years | Any time; includes hemorrhagic/necrotizing forms | Discontinue immediately; do not restart if confirmed; fatal cases reported postmarketing |
| Cholelithiasis / cholecystitis | LEADER: 1.5% / 1.1% vs 1.1% / 0.7% placebo | Months to years; GLP-1 class effect; majority required hospitalization or cholecystectomy | Gallbladder imaging if symptoms develop; surgical referral as indicated |
| Acute kidney injury | Rare (postmarketing) | Often during initiation with GI-related dehydration | Rehydrate; monitor renal function; some cases required hemodialysis; use caution in renal impairment |
| Anaphylaxis / angioedema | Very rare (postmarketing) | Any time | Discontinue permanently; emergency management |
| Medullary thyroid carcinoma | Postmarketing reports | Unknown; causal relationship not established | Contraindicated in MTC/MEN2 history; evaluate neck mass or elevated calcitonin |
| Pulmonary aspiration (peri-procedural) | Rare (postmarketing) | During general anesthesia/deep sedation | Inform anesthesia team; GLP-1 class-wide warning (Nov 2024 label update) |
The 1-week 0.6 mg initiation dose exists solely to improve GI tolerability. Most nausea and vomiting occur during the first 2–3 months and are the primary driver of early discontinuation (4.3% vs 0.5% placebo). Advise patients to eat smaller meals, avoid high-fat foods, and stay well hydrated. If GI symptoms are persistent at 1.2 mg, delay escalation to 1.8 mg. Monitor renal function during severe GI symptoms, as dehydration-related AKI has been reported postmarketing.
Lipase: Mean increase of 33% from baseline; LEADER: ≥3× ULN in 7.9% vs 4.5% placebo. Amylase: Mean increase of 15%; LEADER: ≥3× ULN in 1.0% vs 0.7% placebo. These elevations alone do not indicate pancreatitis — clinical correlation is required. Bilirubin: Mild elevations (≤2× ULN) in 4.0% vs 2.1% placebo. Heart rate: Mean increase of 2–3 bpm. No QTc prolongation at therapeutic doses.
Drug Interactions
Liraglutide is metabolized by endogenous proteolytic pathways without CYP450 involvement, resulting in very low metabolic drug interaction potential. It delays gastric emptying, which can theoretically alter absorption of co-administered oral medications, but clinical pharmacology studies demonstrated no clinically relevant effect on absorption of tested oral drugs (acetaminophen, atorvastatin, griseofulvin, digoxin, lisinopril, oral contraceptives). The primary interaction concern is pharmacodynamic hypoglycemia risk with insulin or secretagogues.
Monitoring
- HbA1cBaseline, then every 3–6 months
RoutinePrimary efficacy marker for Victoza. Expected HbA1c reductions: ~1.0% at 1.2 mg, ~1.1–1.5% at 1.8 mg. LEADER showed ~0.4% sustained difference vs placebo at 3 years. - Body WeightEach visit
RoutinePrimary efficacy marker for Saxenda. Mean weight loss ~5–8% with 3.0 mg. For Victoza, 2–3 kg loss is typical. - Renal FunctionBaseline; during GI symptoms
Trigger-basedUse caution in renal impairment. Postmarketing AKI reports, often with GI-related dehydration. LEADER showed nephropathy HR 0.78 (P=0.003). - Blood GlucoseIncreased with insulin/SU
Trigger-basedSevere hypoglycemia requiring assistance: 7.5 events/1,000 pt-years (7/8 on SU). In pediatrics: hypoglycemia <54 mg/dL in 21.2% (335 events/1,000 pt-years). - Pancreatitis SignsOngoing clinical vigilance
Trigger-based13 cases in glycemic control trials (2.7/1,000 pt-years). Lipase elevations (≥3× ULN: 7.9% LEADER) do not alone indicate pancreatitis. - ThyroidClinical assessment only
Trigger-basedMTC cases reported postmarketing. Routine calcitonin/ultrasound not recommended (low specificity). Evaluate neck mass, dysphagia, persistent hoarseness. Calcitonin >50 ng/L may indicate MTC. - GallbladderIf symptoms develop
Trigger-basedLEADER: cholelithiasis 1.5% vs 1.1% placebo; cholecystitis 1.1% vs 0.7%. Image if right upper quadrant pain develops. - Hepatic FunctionIf symptoms develop
Trigger-basedPostmarketing: hepatitis, cholestasis, elevated liver enzymes reported. Mild bilirubin elevations in 4.0% of trial patients.
Contraindications & Cautions
Absolute Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity to liraglutide or any excipient
Relative Contraindications (Specialist Input Recommended)
- History of pancreatitis — fatal hemorrhagic and necrotizing pancreatitis reported; do not restart if pancreatitis is confirmed
- Gastroparesis (severe) — further delays gastric emptying; use with caution (Section 8.8 of PI)
- Co-administration with other liraglutide or GLP-1 RA products — explicitly prohibited
Use with Caution
- Renal impairment — no dose adjustment needed, but use caution during initiation/escalation; AKI reported postmarketing
- Concomitant insulin or sulfonylureas — proactively reduce dose; pediatric patients have higher hypoglycemia risk regardless of concomitant therapy
- Planned surgery requiring general anesthesia — inform anesthesia team; pulmonary aspiration risk (Nov 2024 label update)
- Pregnancy — use only if potential benefit justifies risk; teratogenic in rats at clinical exposures
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant exposures in both genders of rats and mice. MTC cases in patients treated with liraglutide have been reported postmarketing, though a causal relationship has not been established. Victoza and Saxenda are contraindicated in patients with personal or family history of MTC or MEN 2. Counsel all patients on symptoms of thyroid tumors. Routine calcitonin screening is not recommended.
Patient Counselling
Purpose of Therapy
Liraglutide works by mimicking a natural gut hormone (GLP-1) that helps the body release insulin when blood sugar is high, reduces appetite, and slows digestion. As Victoza, it is injected once daily to improve blood sugar and protect the heart in type 2 diabetes. As Saxenda, it is used at a higher dose for long-term weight management.
How to Use
Inject once a day, at any time, with or without meals, in the abdomen, thigh, or upper arm. Rotate injection sites within each area. Store unused pens in the refrigerator; once in use, a pen can be kept at room temperature for up to 30 days. Never share pens with anyone.
Sources
- Victoza (liraglutide) injection, for subcutaneous use. Full Prescribing Information. Revised November 2024. Novo Nordisk Inc. FDA LabelPrimary source for Victoza dosing, adverse reactions (Table 1), contraindications, PK data, and both diabetes and CV indications.
- Saxenda (liraglutide [rDNA origin]) injection, for subcutaneous use. Full Prescribing Information. Novo Nordisk Inc. FDA LabelSource for Saxenda-specific dosing escalation (up to 3.0 mg) and weight management indication in adults and adolescents.
- Marso SP, Daniels GH, Poulter NR, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827LEADER trial (N=9,340): 13% MACE reduction (HR 0.87; 95% CI 0.78–0.97; P=0.01 superiority); 22% CV death reduction (HR 0.78); 15% all-cause mortality reduction; median follow-up 3.8 years.
- Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–848. doi:10.1056/NEJMoa1616011LEADER renal secondary analysis: 22% reduction in composite renal outcome (HR 0.78; P=0.003); driven by lower new-onset macroalbuminuria.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892SCALE Obesity and Prediabetes trial (N=3,731): mean 8.0% weight loss with liraglutide 3.0 mg vs 2.6% placebo at 56 weeks; pivotal Saxenda weight management trial.
- Tamborlane WV, Barrientos-Perez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637–646. doi:10.1056/NEJMoa1903822ELLIPSE trial (N=135, ages 10–17): HbA1c reduction 0.64% greater than placebo at 26 weeks; basis for pediatric T2DM indication.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1). doi:10.2337/dc25-SINTRecommends GLP-1 RA with proven CV benefit as preferred agent in T2DM with ASCVD; liraglutide qualifies based on LEADER.
- Marx N, Federici M, Schutt K, et al. 2023 ESC Guidelines for CVD management in diabetes. Eur Heart J. 2023;44(39):4043–4140. doi:10.1093/eurheartj/ehad192European guideline positioning GLP-1 RAs as first-line cardiometabolic therapy for T2DM with CVD.
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi:10.3389/fendo.2019.00155Comprehensive account of liraglutide design: C16 fatty acid acylation, 97% GLP-1 homology, albumin-binding protraction mechanism.
- Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55(6):657–672. doi:10.1007/s40262-015-0343-6Detailed PK characterization: bioavailability 55%, Tmax 8–12 h, t1/2 ~13 h, clearance ~1.2 L/h; no clinically relevant PK changes in renal/hepatic impairment.
- Ingwersen SH, Khurana M, Engell RT, Strojek K, Holst AG. Population pharmacokinetics of liraglutide in patients with type 2 diabetes: exposure-response relationships for efficacy and safety. Br J Clin Pharmacol. 2018;84(5):976–988. doi:10.1111/bcp.13525Population PK analysis establishing dose-proportional exposure and consistent exposure-response relationships for HbA1c and body weight across the LIRA clinical program.